Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
about
Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat.Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis.Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.Novel nanoparticulate gel formulations of steroids for the treatment of macular edema.In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits.Modeling of corneal and retinal pharmacokinetics after periocular drug administrationInhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model.Sustained transscleral drug delivery.MRI in ocular drug delivery.Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.Drug, delivery and devices for diabetic retinopathy (3Ds in DR).Applications of polymers in intraocular drug delivery systemsMinimally invasive microneedles for ocular drug delivery.Impedance spectroscopy in monitoring the maturation of stem cell-derived retinal pigment epithelium.Design of an implantable device for ocular drug delivery.Iontophoretic transport of charged macromolecules across human sclera.Characterization of silicone pressure-sensitive adhesive episcleral implant for drug delivery.Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in RabbitsPrinciples of pharmacology in the eye.Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation.Preliminary study of a controllable device for subtenon drug infusion in a rabbit model.Application of Hydrogel Template Strategy in Ocular Drug Delivery.Physicochemical and biological characterization of sustained isopropyl unoprostone-release device made of poly(ethyleneglycol) dimethacrylates.Protective effects of sustained transscleral unoprostone delivery against retinal degeneration in S334ter rhodopsin mutant rats.Hydrogel Ring for Topical Drug Delivery to the Ocular Posterior Segment.A platform for controlled dual-drug delivery to the retina: protective effects against light-induced retinal damage in rats.Dendrimeric systems and their applications in ocular drug delivery.Micro-channel diffusion characteristics of an implantable drug delivery device for age-related macular degeneration
P2860
Q33505319-814122B2-73FE-4D18-8509-B22E92029C3CQ33523210-809BB14A-98BB-4516-88E7-35F31DDCCD07Q34336983-70CE6C8E-5E5D-4EB5-9E69-130DD52435F4Q34862792-94D28AE9-C161-4004-9AA4-B0A3C9446719Q34987327-02F7BF70-810E-4DEF-9DC1-4BC2E2CBEA7FQ35518911-4375CADC-1F5B-43FA-9393-61FA700D9034Q35882664-5B3AFC71-B6D9-4ACB-B9DF-DAF26891CDF1Q36820584-D3CFD42A-0ADF-4D74-A2A2-F3F08DDDBECEQ37039016-3EE93DCB-2302-4EFE-B5EE-031E35796841Q37054230-E1736732-04A0-4786-85D3-939752117340Q38100561-EF1DA453-319A-4374-8B2D-4F3F9EA512F7Q38368715-090A3DE2-01DD-4D9C-852F-BFEECB038E9CQ38829320-EE23A110-7FB9-4F3F-A684-A43BDA0C85A5Q38832441-0BECCCA3-C4A1-4CD2-8882-CEA2D9140EBFQ38904930-05305B15-F8CA-4964-8963-6D4C1140F108Q38916649-3C5F3F9F-C58A-4C6E-9AC9-5330802F9061Q39476810-3CB2C0C9-1615-40ED-8860-38F5432F778CQ39564169-E36E3DCD-38F9-4C5C-ADA2-354D7E7C9690Q39623649-4417AF10-D533-45A4-8D55-E26A48FEA454Q40999904-0AC9A58C-25BC-458F-A1EA-E61919CFD84AQ42321881-0C77F1EC-9D53-438B-B755-46C4DE0B5F72Q45871474-7ECC0824-AC41-41A4-8E98-9CE9FCD62C63Q48220185-FCA8BB46-8578-4C8D-BB65-9FB349D525DEQ48300017-D608A8F4-2410-4169-8A93-0575FCC001E5Q48821505-90A2317A-4460-4E3B-B25E-496760CAC035Q50866267-33556363-7B4F-48DA-9440-9B008B915B48Q51135060-D264457E-B14D-403F-AF86-4747D6EF7F25Q51823268-97355526-B061-4BE7-BD81-231AAF00CF93Q53569057-CD39B1CF-9AB1-4683-9094-01940C7D0AC2Q55563721-5D41F87C-3617-4110-82FE-EBB9A5616892Q58326320-A3DA002E-6055-48A5-BD99-17CFCAF96FD4
P2860
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@ast
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@en
type
label
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@ast
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@en
prefLabel
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@ast
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@en
P1476
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
@en
P2093
Arto Urtti
Veli-Pekka Ranta
P304
P356
10.1016/J.ADDR.2006.07.025
P407
P577
2006-09-16T00:00:00Z